4-hydroxy-2-isopropoxybenzaldehyde | 1165713-47-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-hydroxy-2-isopropoxybenzaldehyde
• 英文别名: 4-Hydroxy-2-isopropoxybenzaldehyde；4-hydroxy-2-propan-2-yloxybenzaldehyde
• CAS: 1165713-47-2
• 化学式: C₁₀H₁₂O₃
• 分子量: 180.203
• InChiKey: LBZMFMUFBZDSGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-isopropoxy-4-methoxymethyloxybenzaldehyde 在 甲醇 、 amberlyst-15 作用下， 以 甲苯 为溶剂， 反应 54.0h， 以74%的产率得到4-hydroxy-2-isopropoxybenzaldehyde
  参考文献：
  名称：

  Factors affecting orthogonality in the deprotection of 2,4-di-protected aromatic ethers employing solid-supported acids

  摘要：

  Selective deprotection of aromatic ethers bearing two protecting groups on the same aromatic ring by solid-supported acids (Amberlyst-15 and PTS-Si) was systematically investigated. ortho-Directing protonation by the carbonyl group as well as carbocation stability and quenching are the important determining factors for the orthogonal deprotection process. Stablilized carbocations (e.g., those from the MOM and PMB groups) could be removed with high selectivity. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2009.03.089

文献信息

• [EN] PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE CETP À BASE D'OXAZOLIDINONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010039474A1

  公开（公告）日：2010-04-08

  The compounds of Formula I are prodrugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.

  公式I的化合物是CETP抑制剂的前药，具有中心噁唑烷酮环。这些化合物在给药后通过消除HX而环化，形成噁唑烷酮环。
• PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS
  申请人：Mills Sander G.

  公开号：US20110218177A1

  公开（公告）日：2011-09-08

  The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.

  公式I的化合物是具有中心噁唑烷环的CETP抑制剂前药。这些化合物在给患者使用后通过HX的消除环化形成噁唑烷环。
• Prodrugs of oxazolidinone CETP inhibitors
  申请人：Mills Sander G.

  公开号：US08354454B2

  公开（公告）日：2013-01-15

  The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.

  式I的化合物是具有中央噁唑烷环的CETP抑制剂的前药。这些化合物在给患者使用后通过消除HX环化形成噁唑烷环。
• US8354454B2
  申请人：——

  公开号：US8354454B2

  公开（公告）日：2013-01-15
• Factors affecting orthogonality in the deprotection of 2,4-di-protected aromatic ethers employing solid-supported acids
  作者：Kassrin Tangdenpaisal、Supannee Sualek、Somsak Ruchirawat、Poonsakdi Ploypradith

  DOI：10.1016/j.tet.2009.03.089

  日期：2009.5

  Selective deprotection of aromatic ethers bearing two protecting groups on the same aromatic ring by solid-supported acids (Amberlyst-15 and PTS-Si) was systematically investigated. ortho-Directing protonation by the carbonyl group as well as carbocation stability and quenching are the important determining factors for the orthogonal deprotection process. Stablilized carbocations (e.g., those from the MOM and PMB groups) could be removed with high selectivity. (C) 2009 Elsevier Ltd. All rights reserved.